Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis
ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcome...
Gespeichert in:
Veröffentlicht in: | Journal of affective disorders 2023-06, Vol.330, p.227-238 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 238 |
---|---|
container_issue | |
container_start_page | 227 |
container_title | Journal of affective disorders |
container_volume | 330 |
creator | de A. Simoes Moreira, Debora Gauer, Luís Eduardo Teixeira, Guilherme Fonseca da Silva, Amanda Carolina Cavalcanti, Stefanie Quevedo, João |
description | ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220).
We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD.
Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential & subgroup analyses were performed.
Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes.
Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT.
•To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD. |
doi_str_mv | 10.1016/j.jad.2023.02.152 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2786511519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032723003245</els_id><sourcerecordid>2786511519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</originalsourceid><addsrcrecordid>eNp9kc1u1DAUha2Kqp0WHoAN8pJNgn8SOwOrqioUqVI3sLY89rVwSOLBN5kqL8Ez4-kUlmyuF-e758rnEPKWs5ozrj70dW99LZiQNRM1b8UZ2fBWy0q0XL8im8K0FZNCX5IrxJ4xpraaXZBLqbZMN6rZkN93IURn3Urt5Kn1B8gIFEIANyNNgf6E2Y5xAnpUFqQwFCUnl6bDMmA8AJ1_QLb7lYaU6Wj7Mj3sM-Cz6COm7CF_pDcUV5xhtHN0NMMhwtPzzbEcqOxkhxUjvibnwQ4Ib17ea_L989232_vq4fHL19ubh8rJrZqroKxjqgu6EbxTvGmE5cpKrSVwx_muZV1rO-nlTkkWyhBeSyZ3zCvhpG7kNXl_8t3n9GsBnM0Y0cEw2AnSgkboTrWct3xbUH5CXU6IGYLZ5zjavBrOzLEG05tSgznWYJgwpYay8-7FftmN4P9t_M29AJ9OAJRPliiyQRdhcuBjLvkan-J_7P8AJaiaNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2786511519</pqid></control><display><type>article</type><title>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>de A. Simoes Moreira, Debora ; Gauer, Luís Eduardo ; Teixeira, Guilherme ; Fonseca da Silva, Amanda Carolina ; Cavalcanti, Stefanie ; Quevedo, João</creator><creatorcontrib>de A. Simoes Moreira, Debora ; Gauer, Luís Eduardo ; Teixeira, Guilherme ; Fonseca da Silva, Amanda Carolina ; Cavalcanti, Stefanie ; Quevedo, João</creatorcontrib><description>ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220).
We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD.
Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential & subgroup analyses were performed.
Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes.
Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT.
•To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD.</description><identifier>ISSN: 0165-0327</identifier><identifier>ISSN: 1573-2517</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2023.02.152</identifier><identifier>PMID: 36907464</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antidepressive Agents - adverse effects ; Depressive Disorder, Major - drug therapy ; ECT ; Electroconvulsive Therapy - adverse effects ; Humans ; Ketamine ; Ketamine - adverse effects ; MDD ; Meta-analysis ; Mood disorders ; Myalgia - drug therapy ; TRD</subject><ispartof>Journal of affective disorders, 2023-06, Vol.330, p.227-238</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</citedby><cites>FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165032723003245$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36907464$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de A. Simoes Moreira, Debora</creatorcontrib><creatorcontrib>Gauer, Luís Eduardo</creatorcontrib><creatorcontrib>Teixeira, Guilherme</creatorcontrib><creatorcontrib>Fonseca da Silva, Amanda Carolina</creatorcontrib><creatorcontrib>Cavalcanti, Stefanie</creatorcontrib><creatorcontrib>Quevedo, João</creatorcontrib><title>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220).
We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD.
Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential & subgroup analyses were performed.
Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes.
Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT.
•To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD.</description><subject>Antidepressive Agents - adverse effects</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>ECT</subject><subject>Electroconvulsive Therapy - adverse effects</subject><subject>Humans</subject><subject>Ketamine</subject><subject>Ketamine - adverse effects</subject><subject>MDD</subject><subject>Meta-analysis</subject><subject>Mood disorders</subject><subject>Myalgia - drug therapy</subject><subject>TRD</subject><issn>0165-0327</issn><issn>1573-2517</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUha2Kqp0WHoAN8pJNgn8SOwOrqioUqVI3sLY89rVwSOLBN5kqL8Ez4-kUlmyuF-e758rnEPKWs5ozrj70dW99LZiQNRM1b8UZ2fBWy0q0XL8im8K0FZNCX5IrxJ4xpraaXZBLqbZMN6rZkN93IURn3Urt5Kn1B8gIFEIANyNNgf6E2Y5xAnpUFqQwFCUnl6bDMmA8AJ1_QLb7lYaU6Wj7Mj3sM-Cz6COm7CF_pDcUV5xhtHN0NMMhwtPzzbEcqOxkhxUjvibnwQ4Ib17ea_L989232_vq4fHL19ubh8rJrZqroKxjqgu6EbxTvGmE5cpKrSVwx_muZV1rO-nlTkkWyhBeSyZ3zCvhpG7kNXl_8t3n9GsBnM0Y0cEw2AnSgkboTrWct3xbUH5CXU6IGYLZ5zjavBrOzLEG05tSgznWYJgwpYay8-7FftmN4P9t_M29AJ9OAJRPliiyQRdhcuBjLvkan-J_7P8AJaiaNg</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>de A. Simoes Moreira, Debora</creator><creator>Gauer, Luís Eduardo</creator><creator>Teixeira, Guilherme</creator><creator>Fonseca da Silva, Amanda Carolina</creator><creator>Cavalcanti, Stefanie</creator><creator>Quevedo, João</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230601</creationdate><title>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</title><author>de A. Simoes Moreira, Debora ; Gauer, Luís Eduardo ; Teixeira, Guilherme ; Fonseca da Silva, Amanda Carolina ; Cavalcanti, Stefanie ; Quevedo, João</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antidepressive Agents - adverse effects</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>ECT</topic><topic>Electroconvulsive Therapy - adverse effects</topic><topic>Humans</topic><topic>Ketamine</topic><topic>Ketamine - adverse effects</topic><topic>MDD</topic><topic>Meta-analysis</topic><topic>Mood disorders</topic><topic>Myalgia - drug therapy</topic><topic>TRD</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de A. Simoes Moreira, Debora</creatorcontrib><creatorcontrib>Gauer, Luís Eduardo</creatorcontrib><creatorcontrib>Teixeira, Guilherme</creatorcontrib><creatorcontrib>Fonseca da Silva, Amanda Carolina</creatorcontrib><creatorcontrib>Cavalcanti, Stefanie</creatorcontrib><creatorcontrib>Quevedo, João</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de A. Simoes Moreira, Debora</au><au>Gauer, Luís Eduardo</au><au>Teixeira, Guilherme</au><au>Fonseca da Silva, Amanda Carolina</au><au>Cavalcanti, Stefanie</au><au>Quevedo, João</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>330</volume><spage>227</spage><epage>238</epage><pages>227-238</pages><issn>0165-0327</issn><issn>1573-2517</issn><eissn>1573-2517</eissn><abstract>ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220).
We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD.
Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential & subgroup analyses were performed.
Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes.
Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT.
•To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36907464</pmid><doi>10.1016/j.jad.2023.02.152</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-0327 |
ispartof | Journal of affective disorders, 2023-06, Vol.330, p.227-238 |
issn | 0165-0327 1573-2517 1573-2517 |
language | eng |
recordid | cdi_proquest_miscellaneous_2786511519 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Antidepressive Agents - adverse effects Depressive Disorder, Major - drug therapy ECT Electroconvulsive Therapy - adverse effects Humans Ketamine Ketamine - adverse effects MDD Meta-analysis Mood disorders Myalgia - drug therapy TRD |
title | Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A06%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20adverse%20effects%20of%20ketamine%20versus%20electroconvulsive%20therapy%20for%20major%20depressive%20disorder:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=de%20A.%20Simoes%20Moreira,%20Debora&rft.date=2023-06-01&rft.volume=330&rft.spage=227&rft.epage=238&rft.pages=227-238&rft.issn=0165-0327&rft.eissn=1573-2517&rft_id=info:doi/10.1016/j.jad.2023.02.152&rft_dat=%3Cproquest_cross%3E2786511519%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2786511519&rft_id=info:pmid/36907464&rft_els_id=S0165032723003245&rfr_iscdi=true |